Recce Pharmaceuticals Limited – Positive Efficacy Data for Inhaled R327 in HAP/VAP Models
Recce Pharmaceuticals Limited (ASX: RCE) has reported strong new preclinical results demonstrating the efficacy of its synthetic anti-infective RECCE® 327 (R327) in validated mouse models of hospital and ventilator-acquired pneumonia caused by multidrug-resistant Acinetobacter baumannii. The study, conducted by the Murdoch Children’s Research Institute, showed that both intranasal and nebulised R327 delivered significant reductions in bacterial load, with nebulised dosing achieving a four-log (>99.99%) decrease and nearing the lower limit of detection.
Early signals of reduced inflammation and favourable tolerability further support its potential as an inhaled therapy for severe pulmonary infections. Unlike meropenem, a standard last-resort antibiotic limited by solubility issues preventing effective nebulisation, R327 can be efficiently aerosolised, offering major practical advantages in critical care settings where direct lung delivery is essential. These findings reinforce R327’s versatility, add to growing evidence of its activity against resistant pathogens, and continue to inform development pathways for future inhaled anti-infective applications.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au.au
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Recce Pharmaceuticals Limited – Positive Efficacy Data for Inhaled R327 in HAP/VAP Models
Recce Pharmaceuticals Limited (ASX: RCE) has reported strong new preclinical results demonstrating the efficacy of its synthetic anti-infective RECCE® 327 (R327) in validated mouse models of hospital and ventilator-acquired pneumonia caused by multidrug-resistant Acinetobacter baumannii. The study, conducted by the Murdoch Children’s Research Institute, showed that both intranasal and nebulised R327 delivered significant reductions in bacterial load, with nebulised dosing achieving a four-log (>99.99%) decrease and nearing the lower limit of detection.
Early signals of reduced inflammation and favourable tolerability further support its potential as an inhaled therapy for severe pulmonary infections. Unlike meropenem, a standard last-resort antibiotic limited by solubility issues preventing effective nebulisation, R327 can be efficiently aerosolised, offering major practical advantages in critical care settings where direct lung delivery is essential. These findings reinforce R327’s versatility, add to growing evidence of its activity against resistant pathogens, and continue to inform development pathways for future inhaled anti-infective applications.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au.au